INNOVATION
they want to get their products straight onto the ward. Some companies are taking the first steps in gathering the evidence base for their products which require clinical based evaluations. Then we will provide them with a costed proposal and then enter into a commercial agreement with a timeline and outline of costs. It is an effective formula for engagement.
“We are currently in a really strong position because we haven’t promoted ourselves in any major way to date. We have worked largely under the radar and have achieved some good successes but we are aware that this will have to change in the hard times ahead and we are prepared for that.”
TrusTECH now has a number of major companies on its books but much of their involvement
which is novel? Does your company offer something which is going to benefit patients? Will this result in a cost reduction to the NHS? We say that if you can tick two or three of these boxes, then we want to do business with you.”
From left to right; Dr Paul Hanmer Adrian Warner Dr Bryan Griffiths
with each other must be kept secret due to confidentiality agreements.
“But I can tell you that we have a number of wound care companies on our books, along with a few biotechnical companies. We also have a number of projects running simultaneously – telehealth is a big, dedicated programme which we are managing. We also have an interest in pressure relief technology and a project
looking at air decontamination technology. A key area for the wider NHS is cutting the vast costs associated with missed appointments and another project we are currently looking at is a technology that will help to reduce those costs, all of which we believe will have a positive impact on the NHS.
“We work with a very simple model which consists of three questions – does your company bring TrusTECH something
TrusTECH has offices in Manchester, Liverpool , Daresbury and Preston but the region stretches from Cheshire to Cumbria. This means that it can offer businesses access to around 60 NHS trusts in the North West.
“We are already becoming much more interactive within the trusts – not just knowing names and addresses of the R&D managers but actually going into those trusts and understanding their broader needs so that we can begin to build meaningful relationships between trusts and suppliers.”
Nov/Dec 10
nhe 55
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100